Based on these results, the FDA approved Zepbound for the treatment of OSA in December 2024, making it the first pharmacological treatment for sleep apnea
That's because the drugs can pass into breastmilk, and this could pose a risk to your baby
In a head-to-head open-label trial reported in February 2026, average weight loss at 84 weeks favored tirzepatide, and the sponsor noted CagriSema did not meet its prespecified non-inferiority target against tirzepatide
Conclusion: Balancing the Benefits and Side Effects of Semaglutide Semaglutide is a powerful tool for losing weight and managing diabetes
Each tablet contains 100 mg ritonavir with the following inactive ingredients: anhydrous dibasic calcium phosphate, colloidal silicon dioxide, copovidone, sodium stearyl fumarate, and sorbitan monolaurate